Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Sinew PharmaROCO:6634 +0.17%25 Median PS Value is NT$0.00 as of Aug. 24, 2026. GuruFocus rates ROCO:6634 with a GF Score™ of 25/100. The stock has 2 warning signs investors should review. Among 282 Biotechnology companies, Sinew Pharma ranks worse than 354609.57% on this metric.
This valuation method assumes that the stock valuation will revert to its historical (10-Year) median in terms of PS Ratio. The reason we use PS Ratio instead of PE Ratio or PB Ratio is because PS Ratio is independent of profit margin, and can be applied to a broader range of situations.
Median PS Value is calculated as trailing twelve months (TTM) Revenue per Share times 10-Year median PS Ratio. Sinew Pharma's Revenue per Share for the trailing twelve months (TTM) ended in Jun. 2026 was NT$0. Sinew Pharma's 10-Year median PS Ratio is . Therefore, the Median PS Value for today is NT$0.00.
As of today (2026-08-24), Sinew Pharma's share price is NT$60.10. Sinew Pharma's Median PS Value is NT$0.00. Therefore, Sinew Pharma's Price to Median PS Value for today is 0.00.
The historical rank and industry rank for Sinew Pharma's Median PS Value or its related term are showing as below:
ROCO:6634's Price-to-Median-PS-Value is not ranked *
in the Biotechnology industry.
Industry Median: 0.62 * Ranked among companies with meaningful Price-to-Median-PS-Value only.
Sinew Pharma (ROCO:6634) Median PS Value Explanation
This valuation method assumes that the stock valuation will revert to its historical (10-Year) mean in terms of PS Ratio. The reason we use PS Ratio instead of PE Ratio or PB Ratio
is because PS Ratio is independent of profit margin, and can be applied to a broader range of situations.
It also assumes that over time the profit margin is constant. If a company increases its profit margin to a sustainable level, this value might under-estimate its value. If it has permanent declined profit margins, this may over-estimate the company's value.
Sinew Pharma's Price to Median PS Value for today is calculated as
Price to Median PS Value
=
Share Price
/
Median PS Value
=
60.10
/
0.00
=
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Sinew Pharma Median PS Value Related Terms
Sinew Pharma Median PS Value Historical Data
* Premium members only.
The historical data trend for Sinew Pharma's Median PS Value can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ROCO:6634 vs VRTX, REGN, RVMD: Median PS Value Comparison
For the Biotechnology subindustry, Sinew Pharma's Price-to-Median-PS-Value, along with its competitors' market caps and Price-to-Median-PS-Value data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Sinew Pharma Price-to-Median-PS-Value vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Sinew Pharma's Price-to-Median-PS-Value distribution charts can be found below:
* The bar in red indicates where Sinew Pharma's Price-to-Median-PS-Value falls into.
10-Year Median PS Ratio is .
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Sinew Pharma's Revenue per Share for the trailing twelve months (TTM) ended in Jun. 2026 was NT$0.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Sinew Pharma (ROCO:6634) has a Median PS Value of NT$0.00 as of Aug. 24, 2026. Median price-sales value is the stock value based on a company's 10-year median price-sales ratio, View historical data on Sinew Pharma and its competitors. According to the industry distribution chart, Sinew Pharma ranks #999999 out of 282 companies in the Biotechnology industry.
Is Sinew Pharma's Median PS Value too high?
Sinew Pharma's current Median PS Value is NT$0.00. Based on the distribution chart, Sinew Pharma ranks #999999 out of 282 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Sinew Pharma has a GF Score™ of 25/100, reflecting its overall financial health beyond just this single metric.
How does Sinew Pharma's Median PS Value compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Sinew Pharma ranks #999999 out of 282 companies for Median PS Value. This places Sinew Pharma in the lower half of its industry. The industry median Median PS Value is 0.62. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Median PS Value for a Biotechnology company?
The median Median PS Value among Biotechnology companies is 0.62, based on 282 companies in the industry. Companies in the top quartile (top 25%) have a Median PS Value significantly above this median, while those in the bottom quartile fall well below. However, Median PS Value should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Median PS Value mean?
A high Median PS Value can signal that a stock is expensive relative to its fundamentals. Median price-sales value is the stock value based on a company's 10-year median price-sales ratio, View historical data on Sinew Pharma and its competitors. For the Biotechnology industry, the median Median PS Value is 0.62 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Sinew Pharma's current Median PS Value is NT$0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sinew Pharma stock overvalued right now?
Sinew Pharma (ROCO:6634) has a current Median PS Value of NT$0.00. The current Median PS Value is NT$0.00. Sinew Pharma's overall GF Score™ is 25/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Median PS Value calculated?
Median PS Value is calculated from a company's financial statements. For Sinew Pharma (ROCO:6634), the current Median PS Value is NT$0.00 as of Aug. 24, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Sinew Pharma Inc is a Taiwan-based biopharmaceutical company. The company is mainly engaged in the research and development of new drugs for the treatment of liver diseases and pain relief. Its drug candidates includes SNP-610, SNP-630, SNP-810, SNP-820, SNP-830 and SNP-840.
25GF Score
Get the complete analysis for ROCO:6634
Median PS Value is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ROCO:6634 has been successfully added to your 
